{"id":"W1976250589","doi":"10.1016/s1470-2045(13)70026-3","title":"Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Amgen","keywords":"Exemestane; Fulvestrant; Postmenopausal women; Medicine; Oncology; Breast cancer; Hormone receptor; Internal medicine; Aromatase inhibitor; Cancer; Gynecology; Aromatase; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001724105,0.002781524,0.003569196,0.0006151525,0.0004143183,0.001116572,0.0009638003,0.002174734,0.009069094],"category_scores_gemma":[0.001850505,0.001036154,0.002334681,0.0005753916,0.00155469,0.001499611,0.0005491875,0.003849036,0.001544934],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008604758,"about_ca_system_score_gemma":0.0009413259,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001329644,"about_ca_topic_score_gemma":0.003019337,"domain_scores_codex":[0.9994752,0.0002518051,0.00002869139,0.0001104014,0.0000364482,0.00009741978],"domain_scores_gemma":[0.9994543,0.0001772747,0.0001067723,0.00005714193,0.00002661511,0.0001779076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9868228,0.001468339,0.0001764516,0.0005771697,0.0005863166,0.00002248801,0.00003234875,0.0002299652,0.001390525,0.00007946928,0.0005995542,0.008014568],"study_design_scores_gemma":[0.9862917,0.01266032,0.0002882697,0.00001374833,0.0001609838,0.00001284455,0.000008652897,0.0001116598,0.0001026868,0.00008008436,0.0002627651,0.00000634817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9693717,0.01326167,0.001313308,0.001825764,0.0020781,0.005754285,0.002443148,0.0003755958,0.003576571],"genre_scores_gemma":[0.9700524,0.007866484,0.002071764,0.001937464,0.0008267664,0.006783455,0.001922522,0.00006447241,0.00847457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009069094,"threshold_uncertainty_score":0.03033912,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03208678168695916,"score_gpt":0.3278753074354844,"score_spread":0.2957885257485253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}